drugset / Trial / NCT00670150
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The safety and efficacy of combining NRX 195183 with arsenic trioxide in treating untreated APL will be assessed.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-08
- Completion
- 2010-08
Outcome
Outcome not reported
Stopped: “sponsor withdrew support”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NRX 195183 | Small molecule | 30 mg/m2 | Oral |
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Other |